Buy WuXi PharmaTech (WX) on Sell-Off, BofA/Merrill Lynch Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
WuXi PharmaTech (WX) Misses Q1 EPS by 9c, Offers Guidance
May 14, 2014 4:36 PM EDTWuXi PharmaTech (NYSE: WX) reported Q1 EPS of $0.30, $0.09 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $146.7 million versus the consensus estimate of $145 million.
Full-Year 2014 Financial Guidance
WuXi PharmaTech announces the following full-year 2014 financial guidance:
Total net revenues of... More
